Haleon plc (NYSE:HLN) Shares Bought by Sei Investments Co.

Sei Investments Co. increased its position in Haleon plc (NYSE:HLN) by 2.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 802,507 shares of the company’s stock after acquiring an additional 21,418 shares during the period. Sei Investments Co.’s holdings in Haleon were worth $6,629,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HLN. Cultivar Capital Inc. bought a new position in Haleon in the 2nd quarter worth about $40,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Haleon during the first quarter worth approximately $43,000. GAMMA Investing LLC boosted its position in shares of Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after buying an additional 3,676 shares during the period. Pinnacle Bancorp Inc. grew its holdings in Haleon by 29.8% in the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after buying an additional 1,421 shares in the last quarter. Finally, Hexagon Capital Partners LLC increased its position in Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after acquiring an additional 2,677 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

HLN opened at $10.59 on Tuesday. The business has a 50 day moving average price of $9.97 and a two-hundred day moving average price of $8.97. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market capitalization of $48.36 billion, a price-to-earnings ratio of 35.30, a price-to-earnings-growth ratio of 3.12 and a beta of 0.26. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter last year, the company earned $0.08 EPS. Research analysts predict that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 33.33%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, Berenberg Bank assumed coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.